Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy
作者： S A Scott , K Sangkuhl , E E Gardner , C M Stein , J-S Hulot
关键词:
摘要: CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19*2 (c.681G>A; rs4244285), is …
gbcbiotech.com
nature.com参考文章(32)
L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. O Braun, J. A. Jakubowski, A. Sugidachi, K. J. Winters, A. Siegbahn, Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease European Heart Journal. ,vol. 29, pp. 21- 30 ,(2007) , 10.1093/EURHEARTJ/EHM545
Tobias Geisler, Elke Schaeffeler, Juergen Dippon, Stefan Winter, Verena Buse, Christian Bischofs, Christine Zuern, Klaus Moerike, Meinrad Gawaz, Matthias Schwab, CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. ,vol. 9, pp. 1251- 1259 ,(2008) , 10.2217/14622416.9.9.1251
Alan R Shuldiner, Jeffrey R O’Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson, Toni I Pollin, Wendy Post, Afshin Parsa, Braxton D Mitchell, Nauder Faraday, William Herzog, Paul A Gurbel, Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy JAMA. ,vol. 302, pp. 849- 857 ,(2009) , 10.1001/JAMA.2009.1232
Matthew J Price, Peter B Berger, Paul S Teirstein, Jean-François Tanguay, Dominick J Angiolillo, Douglas Spriggs, Sanjeev Puri, Mark Robbins, Kirk N Garratt, Olivier F Bertrand, Michael E Stillabower, Joseph R Aragon, David E Kandzari, Curtiss T Stinis, Michael S Lee, Steven V Manoukian, Christopher P Cannon, Nicholas J Schork, Eric J Topol, Gravitas Investigators, None, Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. ,vol. 305, pp. 1097- 1105 ,(2011) , 10.1001/JAMA.2011.290
KA Kim, PW Park, SJ Hong, J-Y Park, The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance Clinical Pharmacology & Therapeutics. ,vol. 84, pp. 236- 242 ,(2008) , 10.1038/CLPT.2008.20
Tabassome Simon, Céline Verstuyft, Murielle Mary-Krause, Lina Quteineh, Elodie Drouet, Nicolas Méneveau, P. Gabriel Steg, Jean Ferrières, Nicolas Danchin, Laurent Becquemont, Genetic Determinants of Response to Clopidogrel and Cardiovascular Events The New England Journal of Medicine. ,vol. 360, pp. 363- 375 ,(2009) , 10.1056/NEJMOA0808227
Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan J Barratt, Jay Horrow, Steen Husted, Hugo Katus, P Gabriel Steg, Svati H Shah, Richard C Becker, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial The Lancet. ,vol. 376, pp. 1320- 1328 ,(2010) , 10.1016/S0140-6736(10)61274-3
Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe, Gilles Montalescot, Witold Ruzyllo, Shmuel Gottlieb, Franz-Joseph Neumann, Diego Ardissino, Stefano De Servi, Sabina A. Murphy, Jeffrey Riesmeyer, Govinda Weerakkody, C. Michael Gibson, Elliott M. Antman, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes The New England Journal of Medicine. ,vol. 357, pp. 2001- 2015 ,(2007) , 10.1056/NEJMOA0706482
Jean-Baptiste Esteve, Johanne Silvain, Laurent Payot, Delphine Brugier, Guillaume Cayla, Farzin Beygui, Gilbert Bensimon, Christian Funck-Brentano, Gilles Montalescot, Jean-Philippe Collet, Jean-Sébastien Hulot, Anna Pena, Eric Villard, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study The Lancet. ,vol. 373, pp. 309- 317 ,(2009) , 10.1016/S0140-6736(08)61845-0
D. SIBBING, D. GEBHARD, W. KOCH, S. BRAUN, J. STEGHERR, T. MORATH, N. VON BECKERATH, J. MEHILLI, A. SCHÖMIG, T. SCHUSTER, A. KASTRATI, Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of Thrombosis and Haemostasis. ,vol. 8, pp. 1685- 1693 ,(2010) , 10.1111/J.1538-7836.2010.03921.X